Physician profile
Robert C Vanzant
NPI 1104821016
$6,031.55
in general payments reported to CMS, 2019-2025
46 companies · $890 in 2025
The $890 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $596 · 2021: $734 · 2022: $851 · 2023: $866 · 2024: $1,154 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,910.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,066.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $718.63 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $413.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $346.49 | 2021-2025 | Vraylar, Ubrelvy, Creon |
| Pfizer INC. | $327.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $287.49 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.53 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $251.73 | 2021-2025 | |
| Amarin Pharma, INC. | $219.20 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $184.04 | 2019-2022 | |
| Astellas Pharma US INC | $151.04 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.52 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $121.65 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $108.39 | 2019-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $99.95 | 2021-2025 | Dexcom G6 Transmitter |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Vanzant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.